Quarterly ResultMay 6, 2026, 07:03 AM
BioCryst Licenses Navenibart European Rights for $70M Upfront; Q1 ORLADEYO Revenue $148.3M
AI Summary
BioCryst Pharmaceuticals reported Q1 2026 financial results, highlighted by ORLADEYO net revenue of $148.3 million, an 11% increase year-over-year. The company also announced a licensing agreement with Neopharmed Gentili for exclusive European commercial rights to navenibart, receiving $70 million upfront and eligibility for up to $275 million in future milestone payments. While BioCryst recorded a GAAP operating loss of $701.6 million due to a significant non-cash R&D expense from the Astria acquisition, its non-GAAP operating profit was $54.2 million. The company maintained its full-year 2026 revenue and non-GAAP operating expense guidance, reflecting continued strong execution and pipeline progress.
Key Highlights
- BioCryst licensed European commercial rights for navenibart for $70M upfront and up to $275M in milestones.
- Q1 2026 ORLADEYO net revenue was $148.3 million, an 11% increase year-over-year.
- The company reported a GAAP operating loss of $701.6 million, primarily due to a $697.8 million non-cash R&D expense.
- Non-GAAP operating profit for Q1 2026 was $54.2 million.
- Cash, cash equivalents, restricted cash, and investments totaled $260.8 million at March 31, 2026.
- Full-year 2026 global net ORLADEYO revenue guidance maintained at $625 million to $645 million.
- Full-year 2026 total revenue guidance maintained at $635 million to $660 million.